Self-reported marijuana use and its effects on overall approval in potential living kidney donors.
kidney transplantation
living donors
marijuana use
Journal
Clinical transplantation
ISSN: 1399-0012
Titre abrégé: Clin Transplant
Pays: Denmark
ID NLM: 8710240
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
revised:
08
06
2022
received:
28
01
2022
accepted:
13
06
2022
pubmed:
1
7
2022
medline:
21
9
2022
entrez:
30
6
2022
Statut:
ppublish
Résumé
Past and present substance use is an important part of the psychosocial evaluation of potential living kidney donors (LKDs). Increasing state legalizations and social acceptance of marijuana (MJ) use can create challenges for transplant centers. We investigated the frequency of reporting MJ use, and its effect on the LKD evaluation. A retrospective chart review was performed on all living donor candidates from December 2016 to December 2019 for reports of MJ use, both on an electronic intake form and during clinical evaluation with a licensed social worker (SW). Active MJ use was defined as current use or use within 1 year of evaluation. Baseline characteristics between MJ users and non-users were compared at each step of donor evaluation. We explored variables associated with MJ use including additional consults and testing during the donor evaluation. Overall approval and donation rates for living donors with active MJ use were compared to non-users. Additionally, 1-year donor follow-up was compared between the two groups. Results of 1818 living donor candidates who completed the intake form, 132 admitted to active MJ use. Compared to non-users, MJ users were more likely to be younger, male, single, renting a home, and with a lower level of education. Thirty three out of 338 candidates who completed a social work evaluation reported MJ use. Compared to non-users, MJ users were more frequently classified as moderate or high risk on SW evaluation, and often required a toxicology screen or psychiatry visit for clearance to donate. Altogether 24.2% of MJ users versus 9.5% of non-users discontinued their evaluation (p < .01). Altogether 42.4% of MJ users versus 56.1% of non-users donated their kidney (p = .13). For those who donated, MJ users were less likely than non-users to follow up at 1 year (57.1% vs. 83.0, p-value .02). MJ users were often asked to complete additional steps in their evaluation before an approval decision was made, which may have led to the higher rate of donor drop out observed in this group. Further research is needed to assess the effects of MJ use on living donor candidacy, as well as any effects of MJ use on long-term donor outcomes.
Sections du résumé
BACKGROUND
Past and present substance use is an important part of the psychosocial evaluation of potential living kidney donors (LKDs). Increasing state legalizations and social acceptance of marijuana (MJ) use can create challenges for transplant centers.
METHODS
We investigated the frequency of reporting MJ use, and its effect on the LKD evaluation. A retrospective chart review was performed on all living donor candidates from December 2016 to December 2019 for reports of MJ use, both on an electronic intake form and during clinical evaluation with a licensed social worker (SW). Active MJ use was defined as current use or use within 1 year of evaluation. Baseline characteristics between MJ users and non-users were compared at each step of donor evaluation. We explored variables associated with MJ use including additional consults and testing during the donor evaluation. Overall approval and donation rates for living donors with active MJ use were compared to non-users. Additionally, 1-year donor follow-up was compared between the two groups. Results of 1818 living donor candidates who completed the intake form, 132 admitted to active MJ use. Compared to non-users, MJ users were more likely to be younger, male, single, renting a home, and with a lower level of education. Thirty three out of 338 candidates who completed a social work evaluation reported MJ use. Compared to non-users, MJ users were more frequently classified as moderate or high risk on SW evaluation, and often required a toxicology screen or psychiatry visit for clearance to donate. Altogether 24.2% of MJ users versus 9.5% of non-users discontinued their evaluation (p < .01). Altogether 42.4% of MJ users versus 56.1% of non-users donated their kidney (p = .13). For those who donated, MJ users were less likely than non-users to follow up at 1 year (57.1% vs. 83.0, p-value .02).
CONCLUSION
MJ users were often asked to complete additional steps in their evaluation before an approval decision was made, which may have led to the higher rate of donor drop out observed in this group. Further research is needed to assess the effects of MJ use on living donor candidacy, as well as any effects of MJ use on long-term donor outcomes.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14758Subventions
Organisme : NIDDK NIH HHS
ID : T32 DK007470
Pays : United States
Informations de copyright
© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Hart A, Lentine KL, Smith JM, et al. OPTN/SRTR 2019 annual data report: kidney. Am J Transplant. 2021;21(2):21-137. https://doi.org/10.1111/ajt.16502
Chadban SJ, Ahn C, Axelrod DA, et al. Summary of the kidney disease: improving global outcomes (KDIGO) clinical practice guideline on the evaluation and management of candidates for kidney transplantation. Transplantation. 2020;104(4):708-714. https://doi.org/10.1097/TP.0000000000003137
Mandelbrot DA, Reese PP, Garg N, et al. KDOQI US commentary on the 2017 KDIGO clinical practice guideline on the evaluation and care of living kidney donors. Am J Kidney Dis. 2020;75(3):299-316. https://doi.org/10.1053/j.ajkd.2019.10.005
Sawinski D, Locke JE. Evaluation of kidney donors: core curriculum 2018. Am J Kidney Dis. 2018;71(5):737-747. https://doi.org/10.1053/j.ajkd.2017.10.018
Rodrigue JR, Pavlakis M, Danovitch GM, et al. Evaluating living kidney donors: relationship types, psychosocial criteria, and consent processes at US transplant programs. Am J Transplant. 2007;7(10):2326-2332. https://doi.org/10.1111/j.1600-6143.2007.01921.x
Garg N, Lentine KL, Inker LA, et al. Metabolic, cardiovascular, and substance use evaluation of living kidney donor candidates: US practices in 2017. Am J Transplant. 2020;20(12):3390-3400. https://doi.org/10.1111/ajt.15964
Hasin DS, Saha TD, Kerridge BT, et al. Prevalence of marijuana use disorders in the united states between 2001-2002 and 2012-2013. JAMA Psychiatry. 2015;72(12):1235-1242. https://doi.org/10.1001/jamapsychiatry.2015.1858
Carliner H, Brown QL, Sarvet AL, Hasin DS. Cannabis use, attitudes, and legal status in the U.S.: a review. Prev Med. 2017;104:13-23. https://doi.org/10.1016/j.ypmed.2017.07.008
Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: a systematic review and meta-analysis [published correction appears in JAMA. 2015 Aug 4;314(5):520] [published correction appears in JAMA. 2015 Aug 25;314(8):837] [published correction appears in JAMA. 2015 Dec 1;314(21):2308] [published correction appears in JAMA. 2016 Apr 12;315(14):1522]. JAMA. 2015;313(24):2456-2473. https://doi.org/10.1001/jama.2015.6358
National Conference of State Legislatures. State Medical Marijuana Laws. https://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx. Accessed October 27, 2021.
Nestoros JN, Vakonaki E, Tzatzarakis MN, Alegakis A, Skondras MD, Tsatsakis AM. Long lasting effects of chronic heavy cannabis abuse. Am J Addict. 2017;26(4):335-342. https://doi.org/10.1111/ajad.12529
Battistella G, Fornari E, Annoni JM, et al. Long-term effects of cannabis on brain structure. Neuropsychopharmacology. 2014;39(9):2041-2048. https://doi.org/10.1038/npp.2014.67
Volkow ND, Baler RD, Compton WM, Weiss SR. Adverse health effects of marijuana use. N Engl J Med. 2014;370(23):2219-2227. https://doi.org/10.1056/NEJMra1402309
Ruckle D, Keheila M, West B, et al. Should donors who have used marijuana be considered candidates for living kidney donation? Clin Kidney J. 2018;12(3):437-442. https://doi.org/10.1093/ckj/sfy107
Loiselle MM, Gulin S, Rose T, Burker E, Bolger L, Smith P. The relationship between marijuana use and psychosocial variables in living kidney donor candidates. Clin Transplant. 2021;35(5):e14248. https://doi.org/10.1111/ctr.14248
Dinitto DM, Choi NG. Marijuana use among older adults in the U.S.A.: user characteristics, patterns of use, and implications for intervention. Int Psychogeriatr. 2011;23(5):732-741. https://doi.org/10.1017/S1041610210002176
Wu LT, Zhu H, Swartz MS. Trends in cannabis use disorders among racial/ethnic population groups in the United States. Drug Alcohol Depend. 2016;165:181-190. https://doi.org/10.1016/j.drugalcdep.2016.06.002
Schulenberg, J. E., Patrick, M. E., Johnston, L. D., O'Malley, P. M., Bachman, J. G., Miech, R. A. (2021). Monitoring the Future national survey results on drug use, 1975-2020: Volume II, college students and adults ages 19-60. Ann Arbor: Institute for Social Research, The University of Michigan, 508 pp. Accessed from http://monitoringthefuture.org/pubs.html#monographs
Bugeja A, Shams I, Harris S, et al. Cannabis and cigarette use before and after living kidney donation. Can J Kidney Health Dis. 2021;8:2054358121997243. https://doi.org/10.1177/2054358121997243
Rein JL. The nephrologist's guide to cannabis and cannabinoids. Curr Opin Nephrol Hypertens. 2020;29(2):248-257. https://doi.org/10.1097/MNH.0000000000000590
Schauer GL, King BA, Bunnell RE, Promoff G, McAfee TA. Toking, vaping, and eating for health or fun: marijuana use patterns in adults, U.S., 2014. Am J Prev Med. 2016;50(1):1-8. https://doi.org/10.1016/j.amepre.2015.05.027
Russell C, Rueda S, Room R, Tyndall M, Fischer B. Routes of administration for cannabis use - basic prevalence and related health outcomes: a scoping review and synthesis. Int J Drug Policy. 2018;52:87-96. https://doi.org/10.1016/j.drugpo.2017.11.008
Adapa S, Gayam V, Konala VM, et al. Cannabis vaping-induced acute pulmonary toxicity: case series and review of literature. J Investig Med High Impact Case Rep. 2020;8:2324709620947267. https://doi.org/10.1177/2324709620947267
Anderson RP, Zechar K. Lung injury from inhaling butane hash oil mimics pneumonia. Respir Med Case Rep. 2019;26:171-173. https://doi.org/10.1016/j.rmcr.2019.01.002
Stephens D, Patel JK, Angelo D, Frunzi J. Cannabis butane hash oil dabbing induced lung injury mimicking atypical pneumonia. Cureus. 2020;12(2):e7033. https://doi.org/10.7759/cureus.7033
Ishida JH, Auer R, Vittinghoff E, et al. Marijuana use and estimated glomerular filtration rate in young adults. Clin J Am Soc Nephrol. 2017;12(10):1578-1587. https://doi.org/10.2215/CJN.01530217
Lu C, Papatheodorou SI, Danziger J, Mittleman MA. Marijuana use and renal function among US adults. Am J Med. 2018;131(4):408-414. https://doi.org/10.1016/j.amjmed.2017.10.051
Bundy JD, Bazzano LA, Xie D, et al. Self-reported tobacco, alcohol, and illicit drug use and progression of chronic kidney disease. Clin J Am Soc Nephrol. 2018;13(7):993-1001. https://doi.org/10.2215/CJN.11121017
Tashkin DP, Baldwin GC, Sarafian T, Dubinett S, Roth MD. Respiratory and immunologic consequences of marijuana smoking. J Clin Pharmacol. 2002;42(S1):71S-81S. https://doi.org/10.1002/j.1552-4604.2002.tb06006.x
Tashkin DP. Effects of marijuana smoking on the lung. Ann Am Thorac Soc. 2013;10(3):239-247. https://doi.org/10.1513/AnnalsATS.201212-127FR
Jouanjus E, Lapeyre-Mestre M, Micallef J; French association of the regional abuse and dependence monitoring centres (CEIP-A) working group on cannabis complications*. Cannabis use: signal of increasing risk of serious cardiovascular disorders. J Am Heart Assoc. 2014;3(2):e000638. https://doi.org/10.1161/JAHA.113.000638
Pletcher MJ, Vittinghoff E, Kalhan R, et al. Association between marijuana exposure and pulmonary function over 20 years. JAMA. 2012;307(2):173-181. https://doi.org/10.1001/jama.2011.1961
Reis JP, Auer R, Bancks MP, et al. Cumulative lifetime marijuana use and incident cardiovascular disease in middle age: the coronary artery risk development in young adults (CARDIA) study. Am J Public Health. 2017;107(4):601-606. https://doi.org/10.2105/AJPH.2017.303654
Sagar KA, Gruber SA. Interactions between recreational cannabis use and cognitive function: lessons from functional magnetic resonance imaging. Ann N Y Acad Sci. 2019;1451(1):42-70. https://doi.org/10.1111/nyas.13990
Galli JA, Sawaya RA, Friedenberg FK. Cannabinoid hyperemesis syndrome. Curr Drug Abuse Rev. 2011;4(4):241-249. https://doi.org/10.2174/1874473711104040241
Bahji A, Stephenson C, Tyo R, Hawken ER, Seitz DP. Prevalence of cannabis withdrawal symptoms among people with regular or dependent use of cannabinoids: a systematic review and meta-analysis. JAMA Netw Open. 2020;3(4):e202370. https://doi.org/10.1001/jamanetworkopen.2020.2370
Habboushe J, Sedor J. Cannabinoid hyperemesis acute renal failure: a common sequela of cannabinoid hyperemesis syndrome. Am J Emerg Med. 2014;32(6):690.e1-690.e6902. https://doi.org/10.1016/j.ajem.2013.12.013
Donnadieu-Rigole H, Olive L, Nalpas B, et al. Follow-up of alcohol consumption after liver transplantation: interest of an addiction team? Alcohol Clin Exp Res. 2017;41(1):165-170. https://doi.org/10.1111/acer.13276
Piccoli GB, Soragna G, Putaggio S, et al. Drug use and kidney donation: what are high-risk behaviors today? Transplant Proc. 2006;38(5):1221-1223. https://doi.org/10.1016/j.transproceed.2006.02.095
Levi ME, Montague BT, Thurstone C, et al. Marijuana use in transplantation: a call for clarity. Clin Transplant. 2019;33(2):e13456. https://doi.org/10.1111/ctr.13456